Investor Presentaiton

Q3 2023 Performance Commercial & Financial Execution Business Development Q3 Global Net Sales • 11.0B; (2%) YoY; (3%) Ex-FX* In-Line Brands & New Product Portfolio • ~$9.3B; +8% YoY; +7% Ex-FX* Earnings per Share (EPS) • GAAP $0.93, +24% YoY Non-GAAP* $2.00, +1% YoY MIRATI THERAPEUTICS Entered into acquisition agreement with planned close by 1H 2024 Strengthens & diversifies Oncology portfolio Financial Outlook Pipeline Execution • Medium-Term Financial Targets* Reaffirms 1: Low-to-mid single digit revenue CAGR² Low double-digit revenue CAGR² ex-Rev/Pom $8-10B revenue growth from in-line brands³ Adjusts: >$10B growth from new product portfolio in 2026 Operating margin to >37%4 Reblozyl: U.S. approval in 1L MDS associated anemia (COMMANDS) Opdivo: U.S. & EU approval in Stage II adj. melanoma (CM-67K); positive Ph3 in SC nivolumab (CM-67T) & peri-adj. lung (CM-77T) LPA, antagonist: Established PoC in PPF ll Bristol Myers Squibb Q3 2023 Results *See "Forward-Looking Statements and Non-GAAP Financial Information" and "Bristol Myers Squibb Company Reconciliation of Certain GAAP Line Items to Certain Non-GAAP Line Items" 1. 2020-2025 Financial Targets 2. At constant exchange rates on a risk-adjusted basis 3. Primarily 1-0 & Eliquis 4. Target through 2025 Not for Product Promotional Use LO 5

View entire presentation